Accordingly, use of ruxolitinib or depletion of STAT3 led to regression of tumor growth in vivo, suggesting that IL-6 or possibility other inducers of JAK:STAT signaling are clearly at play during in vivo acquisition of drug resistance. This evidence concerns the gene IL6 and neoplasm.